Form 4: Haemonetics CEO Christopher Simon Reports Acquisition of Stock and Stock Options

Christopher Simon, President & CEO of Haemonetics Corp, reports the acquisition of restricted stock units and stock options.

Summary

• On May 16, 2025, Christopher Simon, the President & CEO of Haemonetics Corp, reported acquiring 21,405 shares of common stock in the form of restricted stock units (RSUs).
• These RSUs vest in three equal annual installments starting on the first anniversary of the grant date.
• Each RSU represents a contingent right to receive one share of Haemonetics common stock when vested.
• Simon also acquired 46,342 non-qualified stock options with an exercise price of $70.31, vesting in annual increments of 25% beginning on the first anniversary of the grant date, and expiring on 05/16/2032.
• Following the reported transactions, Simon beneficially owns 335,112 shares of common stock, including unvested RSUs, and 46,342 derivative securities.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing. The CEO acquiring stock and options could be seen as a positive signal, but it's not definitive.

Positives

• The acquisition of stock and stock options by the CEO could be interpreted as a sign of confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the holdings and transactions of company executives.

Stakeholder Impact

• The reported transactions may influence investor perception of Haemonetics Corp.

Key Dates

Keywords

Haemonetics, Christopher Simon, Form 4, Stock Options, Restricted Stock Units, Beneficial Ownership, Insider Trading